Researchers at the Institute of General Physics at the Russian Academy of Sciences and the Moscow Institute of Physics and Technology said their advancement in biocomputing using nanoparticles is a step towards creating drug-delivering nanorobots.
The FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 10-3 to recommend approval of Boehringer Ingelheim's mist formulation of its dry-powder inhalable treatment for chronic obstructive pulmonary disease (COPD). If approved, the new product, Spiriva Respimat, would give clinicians an alternative to the company's FDA-approved tiotropium bromide inhalable dry powder, the Spiriva HandiHaler.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier (BBB) opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases. Read more >>
Fresenius Kabi announced Aug. 26 that it has received approval of the Kabiven and Perikabiven, parenteral nutrition products in a three-chamber bag.
AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.
Nanoparticles come in many shapes and sizes, each specifically designed to play a precise role in cancer treatment. And now, researchers from UC Davis have created nanotechnology with the ability to perform multiple tasks and the ultimate goal of destroying tumors.
Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.
The FDA has approved the first needle-free delivery system for the inactivated flu vaccine. The jet injector, made by Pennsylvania-based PharmaJet, has been shown to successfully provide vaccination without a needle jab, which could ultimately help improve vaccination rates.
From Our Sister Sites
A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.
The big deal in contract manufacturing these days is biologics. Patheon is among those investing in facilities to capture more of that business. Patheon parent DPx has agreed to buy Gallus BioPharmaceuticals, presenting Patheon with its first biologics plants in the U.S.